Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.21 +2.00%

+$0.69 today

Market cap
$6.87B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.93M

Average 1.84M

IMVT Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Immunovant, Inc.NASDAQ: IMVT

Operating Margin · Q2 FY2027 · quarter ended Sep 2026

Operating margin not reported for Q2 FY2027

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearMar 2026
—— YoY
LTMSep 2026
-7488.4%— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

No Operating Margin data reported for this period type.

Operating Margin vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 operating margin of -7488.4% is the lowest of the 6 companies compared; the peer median is 17.6%.
IMVT Competitors Peer median
Operating Margin for IMVT and competitors
Company Period LTM level YoY 3-year change
QTTBQ32 Bio Inc.LTM Mar 202639.8% —+621.2 pp
TGTXTG Therapeutics, Inc.LTM Sep 202621.5% +2.2 pp+7859.0 pp
ANABAnaptysBio, Inc.LTM Mar 202617.6% +107.2 pp+1139.8 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-961.9% -168.3 pp-673.9 pp
ZBIOZenas BioPharma, Inc.FY2025-2113.8% +1163.9 pp—
IMVTImmunovant, Inc.LTM Sep 2026-7488.4% ——
TRAXFirst Tracks Biotherapeutics IncFY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
ANNXAnnexon, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
Peer median (excluding IMVT) 17.6%+54.7 pp+880.5 pp

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development101.81M160.26M212.93M360.92M456.66M
Selling, General & Admin54.23M48.02M57.28M77.24M76.24M
Operating Expenses156.03M208.28M270.21M438.15M532.9M
Depreciation & Amortization126K193K231K377K409K
EBITDA(156.69M)(198.28M)(258.54M)(412.57M)(504.98M)
EBITDA Margin—————
Operating Income(156.03M)(208.28M)(270.21M)(438.15M)(532.9M)
Operating Margin—————
Interest Income07.58M24.95M24.73M25.33M
Interest Expense012.48M000
Other Income / Expenses(781K)(2.68M)11.44M25.2M27.51M
Income Before Tax(156.81M)(210.95M)(258.77M)(412.95M)(505.39M)
Pre-Tax Margin—————
Income Tax Expense(84K)9K567K891K215K
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Net Margin—————
EPS (Basic)(1.43)(1.71)(1.88)(2.73)(2.77)
EPS (Diluted)(1.43)(1.71)(1.88)(2.73)(2.77)
Weighted Avg Shares109.68M123.08M138.1M151.57M182.42M
Weighted Avg Shares (Diluted)109.68M123.08M138.1M151.57M182.42M

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.